Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Chimerix, USAMRIID in smallpox drug pact

April 24, 2006 | A version of this story appeared in Volume 84, Issue 17

Research Triangle Park, N.C.based Chimerix and the United States Army Medical Research Institute of Infectious Diseases have teamed up to develop Chimerix' smallpox drug. The agreement allows Chimerix to test its smallpox drug candidate CMX001 and others against USAMRIID's animal models of smallpox and monkey pox infection. Chimerix uses lipid conjugate technology to modify drug molecules to mimic natural lipid metabolites. The change enables absorption and controlled distribution of the drug throughout the body. CMX001 is an oral antiviral that is being tested to treat both smallpox infection and complications resulting from smallpox vaccination. Chimerix previously received a $36.1 million grant from NIH to develop the drug.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.